The Latest Cardiac and Vascular News
ATLANTA, April 16, 2024 /PRNewswire/ — Annoviant™, Inc., a pioneering company with a breakthrough TxGuard™ technology platform for soft-tissue healing, currently focused on cardiovascular field, proudly announces receipt of a $2.99 million grant (SBIR Phase 2b) from the National…
Funding will help drive commercialization of next-generation pulmonary valve conduit for pediatric patients ATLANTA–(BUSINESS WIRE)–Annoviant LLC, formerly TGen Tech LLC, today announced that it has been awarded a grant of $1.85 million for two years by the National Institutes of Health (NIH) to help further its development and commercialization of […]
